Donor Lymphocyte Infusion — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	2	2	3	12	0	—	—	2010-02
Leukemia	Phase3	Phase 3	2	2	1	8	0	—	—	2013-12

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 8 hours agoSource updated unknown

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT3 Fusion1
Bone Marrow Transplantation +

Clinical trials

Trials with this intervention (12)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–12 of 12 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05772273	PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT	recruiting	N/A	43	The First Affiliated Hospital of Soochow UniversityOTHER	1	Sep 2, 2026	clinicaltrials
NCT06158100	Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)